Cadila gets final USFDA approval to market Deferasirox tablets

Zydus Cadila, part of Cadila Healthcare has informed the bourses that it has received a final approval to market Deferasirox tablets.

The company has received USFDA nod to market Deferasirox tablets (90 mg, 180 mg and 360 mg), which is used for treating high levels of iron in patients, having a certain blood disorder.

Since the commencement of the filing process in FY 2003-04, the group now has 291 approvals and has filed over 386 abbreviated new drug applications (ANDA).

Earlier in May 2020, USFDA had granted tentative approval to the company to market Droxidopa capsules, which treats low blood pressure.

Besides, in May 2020, the company had received an establishment inspection report (EIR) for Baddi (Himachal Pradesh) facility where an inspection was conducted from March 02 to March 09, 2020, which ended with nil observations.

Read it here: https://www.dsij.in/DSIJArticleDetail/ArtMID/10163/ArticleID/13106/Cadila-Healthcare-receives-EIR-for-Baddi-facility-from-USFDA

Cadila's revenue mix comprised of US formulations (50 per cent), India formulations (29 per cent), EMB formulations (six per cent), animal health (four per cent), wellness (four per cent), API (three per cent), alliances (two per cent) and Europe formulations (two per cent).

Today, the stock of Cadila Healthcare opened at Rs 365.95 and made an intraday high of Rs 374.65 on BSE.